Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid

Alzheimer's and Dementia

Volumn 12, Issue 5, 2016, Pages 517-526

  Bittner, Tobias ^a   Zetterberg, Henrik ^b,c   Teunissen, Charlotte E ^d   Ostlund, Richard E ^e   Militello, Michael ^f   Andreasson, Ulf ^b   Hubeek, Isabelle ^d   Gibson, David ^e   Chu, David C ^f   Eichenlaub, Udo ^a   Heiss, Peter ^a   Kobold, Uwe ^a   Leinenbach, Andreas ^a   Madin, Kairat ^a   Manuilova, Ekaterina ^a   Rabe, Christina ^a   Blennow, Kaj ^b  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Labcorp Drug Development   (United States)

Author keywords

Alzheimer's disease; Amyloid; Amyloid beta 1 42; Assay; Biomarker; Cerebrospinal fluid; Dementia; Diagnosis; Electrochemiluminescence; Immunoassay; Method comparison; Precision; Repeatability; Reproducibility; Variability

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; HUMAN; IMMUNOASSAY; IMMUNOASSAY ANALYZER; LIMIT OF QUANTITATION; LINEAR SYSTEM; LIQUID CHROMATOGRAPH; LIQUID CHROMATOGRAPHY; MASS SPECTROMETER; MEASUREMENT REPEATABILITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REPRODUCIBILITY; STANDARDIZATION; TANDEM MASS SPECTROMETRY; ALZHEIMER DISEASE; CEREBROSPINAL FLUID; DEVICES; LUMINESCENCE; PROCEDURES; STANDARD; STANDARDS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; HUMANS; IMMUNOASSAY; LUMINESCENCE; PEPTIDE FRAGMENTS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS;

EID: 84952053119     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2015.09.009     Document Type: Article

References (51)

1. L.E. Hebert, J. Weuve, P.A. Scherr, and D.A. Evans Alzheimer disease in the United States (2010-2050) estimated using the 2010 census Neurology 80 2013 1778 1783
2. Wimo A, Jonsson L, Gustavsson A. Available at: http://www.alzheimer-europe.org/EN/Research/European-Collaboration-on-Dementia/Cost-of-dementia/Prognosis-to-2030. Accessed October 27, 2009.
3. J.L. Cummings, T. Morstorf, and K. Zhong Alzheimer's disease drug-development pipeline: Few candidates, frequent failures Alzheimers Res Ther 6 2014 37
4. B. Dubois, H.H. Feldman, C. Jacova, H. Hampel, J.L. Molinuevo, K. Blennow, and et al. Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria Lancet Neurol 13 2014 614 629
5. I.A. van Rossum, S.J. Vos, L. Burns, D.L. Knol, P. Scheltens, H. Soininen, and et al. Injury markers predict time to dementia in subjects with MCI and amyloid pathology Neurology 79 2012 1809 1816
6. P. Buchhave, L. Minthon, H. Zetterberg, A.K. Wallin, K. Blennow, and O. Hansson Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia Arch Gen Psychiatry 69 2012 98 106
7. L.M. Shaw, H. Vanderstichele, M. Knapik-Czajka, C.M. Clark, P.S. Aisen, R.C. Petersen, and et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Ann Neurol 65 2009 403 413
8. D. Strozyk, K. Blennow, L.R. White, and L.J. Launer CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study Neurology 60 2003 652 656
9. S. Palmqvist, H. Zetterberg, K. Blennow, S. Vestberg, U. Andreasson, D.J. Brooks, and et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: A cross-validation study against amyloid positron emission tomography JAMA Neurol 71 2014 1282 1289
10. V. Coric, J. Seibyl, M. Mintun, J. Ross, M. Brody, C. Curtis, and et al. Correlation between baseline measures of amyloid-positron emission tomography (PET) imaging, cerebral spinal fluid (CSF) biomarkers, and clinical scales in predementia Alzheimer's disease Alzheimers Dement 7 2011 S209
11. S.M. Landau, M. Lu, A.D. Joshi, M. Pontecorvo, M.A. Mintun, J.Q. Trojanowski, et al. for the Alzheimer's Disease Neuroimaging Initiative Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid Ann Neurol 74 2013 826 836
12. S.J. Vos, P.J. Visser, F. Verhey, P. Aalten, D. Knol, I. Ramakers, and et al. Variability of CSF Alzheimer's disease biomarkers: Implications for clinical practice PLoS One 9 2014 e100784
13. N. Mattsson, U. Andreasson, S. Persson, M.C. Carrillo, S. Collins, S. Chalbot, and et al. CSF biomarker variability in the Alzheimer's Association Quality Control Program Alzheimers Dement 9 2013 251 261
14. N. Mattsson, I. Zegers, U. Andreasson, M. Bjerke, M.A. Blankenstein, R. Bowser, and et al. Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: Definitions and approaches with focus on amyloid-β 42 Biomark Med 6 2012 409 417
15. K. Johnson-Wood, M. Lee, R. Motter, K. Hu, G. Gordon, R. Barbour, and et al. Amyloid precursor protein processing and Ab42 deposition in a transgenic mouse model of Alzheimer disease Proc Nat Acad Sci 94 1997 1550 1555
16. M. Jensen, T. Hartmann, B. Engvall, R. Wang, S.N. Uljon, K. Sennvik, and et al. Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems Mol Med 6 2000 291 302
17. Clinical Laboratory and Standards Institute (CLSI) Evaluation of detection capability for clinical laboratory measurement procedures: Approved guideline - Second edition. CLSI Document EP17-A2 2012 Clinical Laboratory and Standards Institute Wayne, PA, USA
18. Clinical Laboratory and Standards Institute (CLSI) Evaluation of the linearity of quantitative measurement procedures: A statistical approach; approved guideline. CLSI Document EP06-A 2003 Clinical Laboratory and Standards Institute Wayne, PA, USA
19. A. Leinenbach, J. Pannee, T. Dulffer, A. Huber, T. Bittner, U. Andreasson, et al. for the IFCC Scientific Division Working Group on CSF proteins Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid Clin Chem 60 2014 987 994
20. Clinical Laboratory and Standards Institute (CLSI) Measurement procedure comparison and bias estimation using patient samples; approved guideline - Third edition. CLSI Document EP09-A3 2013 Clinical Laboratory and Standards Institute Wayne, PA, USA
21. H. Passing, and W. Bablok A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I J Clin Chem Clin Biochem 21 1983 709 720
22. Clinical Laboratory and Standards Institute (CLSI) Interference testing in clinical chemistry; approved guideline - Second edition. CLSI Document EP7-A2 2005 Clinical Laboratory and Standards Institute Wayne, PA, USA
23. Clinical Laboratory and Standards Institute (CLSI) Immunoassay interference by endogenous antibodies; approved guideline. CLSI Document I/LA30-A 2008 Clinical Laboratory and Standards Institute Wayne, PA, USA
24. E. Portelius, H. Zetterberg, J. Gobom, U. Andreasson, and K. Blennow Targeted proteomics in Alzheimer's disease: Focus on amyloid-beta Expert Rev Proteomics 5 2008 225 237
25. Clinical Laboratory and Standards Institute (CLSI) Evaluation of precision of quantitative measurement procedures; approved guideline - Third edition. CLSI Document EP05-A3 2014 Clinical Laboratory and Standards Institute Wayne, PA, USA
26. Clinical Laboratory and Standards Institute (CLSI) User verification of performance for precision and trueness; approved guideline - Second edition. CLSI Document EP15-A2 2014 Clinical Laboratory and Standards Institute Wayne, PA, USA
27. K. Blennow, and H. Zetterberg The Alzheimer's Association QC program for CSF biomarkers. Round 16 results 2015 Available at: http://neurophys.gu.se/digitalAssets/1520/1520761-2014-16-summary.pdf. Accessed January 29, 2015
28. K. Blennow, and H. Zetterberg The Alzheimer's Association QC program for CSF biomarkers. Round 17 results 2015 Available at: http://neurophys.gu.se/digitalAssets/1525/1525893-2015-17-summary.pdf. Accessed April 28, 2015
29. J. Kang, M. Korecka, J.B. Toledo, J.Q. Trojanowski, and L.M. Shaw Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and tau proteins as Alzheimer disease biomarkers Clin Chem 59 2013 903 916
30. World Health Organization Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Abbreviated report of a WHO consultation 2011 WHO/NMH/CHP/CPM/11.1
31. G. Humbert, A. Leroy, J.P. Rogez, and C. Cherubin Cefoxitin concentrations in the cerebrospinal fluids of patients with meningitis Antimicrob Agents Chemother 17 1980 675 678
32. A.J. Scheen Clinical pharmacokinetics of metformin Clin Pharmacokinet 30 1996 359 371
33. M. Bjerke, E. Portelius, L. Minthon, A. Wallin, H. Anckarsäter, R. Anckarsäter, and et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid Int J Alzheimers Dis 2010 2010 1 11
34. H. Vanderstichele, M. Bibl, S. Engelborghs, N. Le Bastard, P. Lewczuk, J.L. Molinuevo, and et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative Alzheimers Dement 8 2012 65 73
35. K. Blennow, N. Mattsson, M. Scholl, O. Hansson, and H. Zetterberg Amyloid biomarkers in Alzheimer's disease Trends Pharmacol Sci 36 2015 297 309
36. Lilly USA Amyvid (Florbetapir F 18 Injection) for intravenous use. Prescribing information 2012 Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/202008s000lbl.pdf. Accessed June 6, 2012.
37. GE Healthcare VIZAMYL (flutemetamol F 18 injection) for intravenous use. Prescribing information 2013 Avaliable at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/203137s000lbl.pdf. Accessed October 25, 2013
38. Piramal Imaging SA NEURACEQ (florbetaben F 18 injection), for intravenous use. Prescribing information 2014 Avaliable at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/204677s000lbl.pdf. Accessed March 19, 2014.
39. K. Blennow, A. Wallin, and O. Hager Low frequency of post-lumbar puncture headache in demented patients Acta Neurol Scand 88 1993 221 223
40. N. Andreasen, L. Minthon, P. Davidsson, E. Vanmechelen, H. Vanderstichele, B. Winblad, and et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice Arch Neurol 58 2001 373 379
41. E. Peskind, A. Nordberg, T. Darreh-Shori, and H. Soininen Safety of lumbar puncture procedures in patients with Alzheimer's disease Curr Alzheimer Res 6 2009 290 292
42. H. Zetterberg, K. Tullhog, O. Hansson, L. Minthon, E. Londos, and K. Blennow Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients Eur Neurol 63 2010 326 330
43. Piramal Imaging Limited Neuraceq: EPAR - Product Information 2014 Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--Product-Information/human/002553/WC500162592.pdf. Accessed November 3, 2015
44. S. Salloway, R. Sperling, N.C. Fox, K. Blennow, W. Klunk, M. Raskind, and et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease N Engl J Med 370 2014 322 333
45. R.S. Doody, R.G. Thomas, M. Farlow, T. Iwatsubo, B. Vellas, S. Joffe, et al. for the Alzheimer's Disease Cooperative Study Steering Committee, Solanezumab Study Group Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease N Engl J Med 370 2014 311 321
46. P. Scheltens, M. Boada, E. Dorflinger, T. Nikolcheva, E. Ashford, D. Volz, et al. on behalf of the SCarlet RoAD investigators Baseline patient characteristics from the phase 3 SCarlet RoAD trial, a study of gantenerumab in patients with prodromal AD J Prev Alzheimers Dis 1 2014 231
47. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., C.H. Kawas, and et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 263 269
48. M. Riemenschneider, S. Wagenpfeil, H. Vanderstichele, M. Otto, J. Wiltfang, H. Kretzschmar, and et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias Mol Psychiatry 8 2003 343 347
49. T. Skillback, C. Rosen, F. Asztely, N. Mattsson, K. Blennow, and H. Zetterberg Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: Results from the Swedish Mortality Registry JAMA Neurol 71 2014 476 483
50. H. Hampel, K. Buerger, R. Zinkowski, S.J. Teipel, A. Goernitz, N. Andreasen, and et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study Arch Gen Psychiatry 61 2004 95 102
51. P. Rosa-Neto, G.Y. Hsiung, M. Masellis for the CCDTD4 participants Fluid biomarkers for diagnosing dementia: Rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians Alzheimers Res Ther 5 2013 S8